Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547945 | 0.84 | ESR1 (0.52) | CA2CA1ESR1HSD17B10CYP1A2 | |
| SCHEMBL74006 | 0.81 | IDO1 (0.52) | ESR1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL2600039 | 0.81 | ALOX15 (0.59) | CA2CA1ESR1HSD17B10CYP1A2 | |
| SCHEMBL4458261 | 0.80 | CA2 (0.52) | CA2CA1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL25596189 | 0.79 | CA2 (0.47) | CA2CA1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL6718607 | 0.78 | CYP1A2 (0.74) | CA2CA1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL6348579 | 0.78 | CYP1A2 (0.74) | CA2CA1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL12867268 | 0.78 | CNR1 (0.46) | CA2CA1ESR1HSD17B10CYP1A2 | |
| SCHEMBL6348576 | 0.78 | CYP1A2 (0.74) | CA2CA1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL631374 | 0.78 | CNR1 (0.64) | CA2CA1HSD17B10CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | GHSR, GHRHR, GIPR | CA2 4764/4885CA1 4864/4885ESR1 506/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | CA2 4816/4885CA1 4877/4885ESR1 925/4885 |
| US-20130150376-A1 | Novel Sultam Compounds | SULT2A1, SULT1A1, SULT1E1 | CA2 2009/4885CA1 1213/4885ESR1 2893/4885 |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | CA2 4120/4885CA1 4214/4885ESR1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.